We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Japan’s Ministry of Health, Labour and Welfare has approved Biocon’s insulin glargine, the eighth biosimilar backed by the regulator since 2009. Read More
A federal jury ruled that Gilead Sciences must dole out $200 million in damages to Merck and Ionis Pharmaceuticals for patent infringement over the active ingredient sofosbuvir in Gilead’s blockbuster hepatitis C drugs. Read More
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit has upheld two Depomed patents, enabling it to resume its lawsuit against Purdue Pharma. Read More
Merck won a key court victory late Tuesday with a jury concluding that two of Gilead Science’s blockbuster drugs infringe patents held by Merck & Co. and Ionis Pharmaceuticals. Read More